MedTrace Logo

[18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity

NCT05806333 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-10

No results posted yet for this study

Summary

Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. We aim to conduct a prospective study to investigate the diagnostic perfoemance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.

Conditions

Interventions

DIAGNOSTIC_TEST

FAPI PET

Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans

Sponsors & Collaborators

  • Jilin University

    lead OTHER

Principal Investigators

  • Bin Ji · China-Japan Union Hospital, Jilin University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05806333 on ClinicalTrials.gov